ClinicalTrials.gg
CompletedNCT06110923Updated Jan 14, 2026

A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846

A Phase 1 interventional study of CKD-846 and D091 in Benign Prostate Hypertrophy(BPH), sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in South Korea. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of — 6 open to participants now, 6 under way, none of them phase 3. Prostatic Hyperplasia · Korea, Republic of.

Enrollment
48th of 57
31 · median 83
Started
2023
with 2 others
Phase 1
20 of 72
4 open now
Registered
64th of 72
by date
Lead sponsor
7 of 72
Chong Kun Dang Pharmaceutical

Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, this one is the 48th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2023, is one of 20 in phase 1, and was the 64th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

6 of the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846

Read the detailed description

A randomized, open-label and parallel study to evaluate the pharmacokinetics and safety of CKD-846 in healthy male subjects

03

Conditions studied

  • Benign Prostate Hypertrophy(BPH)

Browse trials for

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy man aged between 19 to 55 at screening
  2. Weight ≥ 55kg
  3. (BMI) of 18.5 to 27.0kg/m2
  4. Those who agree to from the first Product (IP) dosing day till 6 months after the last dosing day and decide not to provide sperm during the participation of clinical trial
  5. Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Those who have disease or medical history of Hepatopathy, Renal, Neurological, Immunity, Respiratory, Endocrine, urinary, tumor or Psychical disorder
  2. Those who have a history of clinically significant cardiovascular diseases such as myocardial infarction, angina pectoris, ventricular arrhythmia, heart failure, left ventricular outflow tract stenosis, stroke, and within 2 years prior to the first administration of the drug

    • Those who have had myocardial infarction within the last 90 days
    • Those who have had unstable angina or angina that occurred during sexual intercourse
    • Those who have had heart failure of class 2 or higher in the past 6 months
    • Those who have had a stroke within the last 6 months
  3. Those with the following eye diseases

    • Those with known genetic degenerative retinal diseases, including retinitis pigmentosa
    • People who have lost vision in one eye due to non-arteritic anterior ischemic optic neuropathy
  4. Those with a past history of erection lasting more than 4 hours and priapism (erection accompanied by pain for more than 6 hours) while taking PDE5 inhibitors such as tadalafil
  5. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption
  6. Persons with a history of clinically significant to drugs or additives, including ingredients of clinical investigational drugs
  7. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  8. A person who is judged to be unsuitable as a test subject in a screening test (screening items such as questionnaire, blood pressure, 12-lead , physical examination, clinical laboratory test, etc.) conducted within 28 days before administration of the investigational drug

    • (AST), Alanine aminotransferase (ALT) > 1.5 times higher than upper normal level
    • Total > 1.5 times higher than upper normal level
    • Epidermal Growth Factor Receptor () (estimated Glomerular Filtration Rate, which is calculated by MDRD) \< 60 mL/min/1.73m2
    • "Positive" or "Reactive" test result of \& C, , rapid plasma reagin test (RPR) > 10.0 ng/mL
    • Prostate specific antigen (PSA)
    • Under 5 min resting condition, systolic blood pressure >150 mmHg or or \<90 mmHg, diastolic blood pressure >100 mmHg or \<50mmHg.
  9. Those who has a drug abuse history within one year or positive reaction on urine drug screening test.
  10. Those who have taken the following drugs, excluding topical drugs without significant systemic absorption, within the relevant period and it is judged that the administered drugs may affect this study or affect the safety of subjects

    • Over the counter (OTC), vitamins, health supplement within 7 days before the first dose of the investigational drug
    • Ethical drug (ETC), herbal medicinal preparations within 14 days before the first dose of the investigational drug
    • inhibitors or CYP3A4 inducers within 30 days before the first dose of the investigational drug
    • Depot injection or implantation within 30 days before the first dose of the investigational drug
  11. Persons who must take the following drugs regularly and/or intermittently during the clinical trial period

    • Nitrate preparations or NO donors
    • Alpha blockers
    • GC stimulators
  12. Those who continuously smoke excessively or consume caffeine or alcohol (cigarettes: >10 cigarettes/day, caffeine: >5 cups/day, alcohol: >210 g/week)
  13. A person who consumed food containing grapefruit within 7 days before the first administration of the investigational drug (e.g., a person who consumed more than 1L of grapefruit-containing beverages per day within 7 days before the first administration of the investigational drug)
  14. Persons who participated in another clinical trial (including bioequivalence test) and received an investigational drug within 180 days prior to the date of first administration of the investigational drug (in the case of biological products, the period may be extended considering the half-life)
  15. Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days
  16. Those who have received blood transfusion in 30 days
  17. Those who are deemed insufficient to participate in clinical study by investigators
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    A1 (Test group)

    CKD-846 A, Single dose

    Drug: CKD-846

  • Experimental
    R (Reference group)

    D091, Multi dose

    Drug: D091

  • Experimental
    A2 (Test group)

    CKD-846 A, Single dose

    Drug: CKD-846

  • Experimental
    B2 (Test group)

    CKD-846 B, Single dose

    Drug: CKD-846

  • Experimental
    A3 or B3 (Test group)

    CKD-846 A or B, Single dose

    Drug: CKD-846

Interventions

  • DrugCKD-846

    once administration of Investigational Product

    Also known as: Investigational Product(Test)

  • DrugD091

    once administration of Investigational Product per day

    Also known as: Investigational Product(Reference)

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of CKD-846

    Concentration of During the administration period

    Time frame: Pre-dose, Post-dose 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 10, 24 hours (During the administration period)

  2. Concentration of D091

    Concentration of During the administration period

    Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

Secondary outcomes

  1. CKD-846 of AUCinf

    Area under the curve

    Time frame: Pre-dose, Post-dose 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 10, 24 hours (During the administration period)

  2. CKD-846 of Tmax

    Time to maximum plasma concentration

    Time frame: Pre-dose, Post-dose 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 10, 24 hours (During the administration period)

  3. CKD-846 of t1/2

    Terminal elimination half-life

    Time frame: Pre-dose, Post-dose 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 10, 24 hours (During the administration period)

  4. CKD-846 of CL/F

    Apparent clearance of drug in plasma

    Time frame: Pre-dose, Post-dose 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 10, 24 hours (During the administration period)

  5. CKD-846 of Vd/F

    Apparent volume of distribution

    Time frame: Pre-dose, Post-dose 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 10, 24 hours (During the administration period)

  6. D091 of Cmax

    Maximum concentration of drug in plasma

    Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

  7. D091 of AUCt

    Area under the curve

    Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

  8. D091 of AUCinf

    Area under the curve

    Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

  9. D091 of Tmax

    Time to maximum plasma concentration at steady state

    Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

  10. D091 of t1/2

    Terminal elimination half-life

    Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

  11. D091 of CL/F

    Apparent clearance of drug in plasma

    Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

  12. D091 of Vd/F

    Apparent volume of distribution

    Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

07

Study locations

1 site
  • Severance Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in May 2024, 5 months.

Of 26 industry-sponsored phase 1 interventional studies under Prostatic Hyperplasia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 4. This study's 5 months is above that.

Counting every sponsor, half of 34 studies reached it within 3 months; a quarter within 1 and three quarters within 6.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Nov 1, 2023
StartActual
Nov 13, 2023
Primary completionActual
May 10, 2024
CompletionActual
Mar 25, 2025
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06110923
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Nov 13, 2023
Primary completion
May 10, 2024
Completion
Mar 25, 2025
Last update
Jan 14, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion